Age/sex
Allergen
Basal tryptase level (µg/L)
Severity of first reaction
Treatment of first reaction
Severity of second reaction
Time to second phase (hr)
Biphasic manifestations
Management location
Asthma
Cardiovascular
Cardiovascular
Atopy
41/F ATB 10.8 III EPI, AH, CS III 2 Cutaneous, cardiovascular ED No No No Yes
23/M ATB 5.4 II AH, CS I 14 Cutaneous Outpatient Yes Yes No Yes
59/M NMBAs 12.4 III EPI, AH, CS II 3 Cutaneous, respiratory Hospital No No No No
38/F NMBAs 22.2 II EPI. AH I 2 Cutaneous Hospital Yes Yes Yes No
29/F NMBAs 5.2 II EPI, AH, CS III 2 Cutaneous, cardiovascular ICU Yes Yes No Yes
26/M NMBAs 11.6 III EPI, AH, CS III 1 Cutaneous respiratory, cardiovascular ICU No No No Yes
76/F Hymen. 8.5 III EPI, AH, CS III 8 Cardiovascular, cutaneous, respiratory ICU No No No No
62/M Hymen. 6.5 III EPI, AH, CS III 1.5 Cutaneous, cardiovascular ED No No Yes No
56/M Hymen. 3.9 III EPI. AH II 12 Cutaneous, respiratory ED Yes Yes No Yes
47/F Hymen. 1.7 III EPI, AH, CS III 3 Cutaneous, cardiovascular ICU No No Yes Yes
53/F Hymen. 3.2 II AH, CS I 48 Cutaneous Outpatient No No No Yes
71/F Hymen. 6.1 II AH, CS II 5 Cutaneous, cardiovascular ED Yes Yes Yes Yes
67/F Food 4.6 II AH II 1.5 Cardiovascular, digestive ED Yes Yes No Yes